Pharmacotherapy for Management of ‘Kratom Use Disorder’: A Systematic Literature Review With Survey of Experts

Cornel Stanciu, MD, MRO; Saeed Ahmed, MD; Bryan Hybki, MD; Thomas Penders, MS, MD; David Galbis-Reig, MD

ABSTRACT

Objectives: An increasing number of Americans are turning to kratom for self-management of various pain, anxiety, and mood states and as an opioid substitute. Addiction to this unique botanical develops and carries a high relapse risk and, to date, there are no guidelines on how to maintain long-term abstinence. The aim of this article is to compile all available information on management of “kratom use disorder” (KUD)—as coined here—from the literature, with evidence from the clinical practice of expert addictionologists in an attempt to develop a standard of care consensus.

Methods: A systematic literature search was conducted to capture all relevant cases pertaining to maintenance treatment for KUD. Results were supplemented with case reports and scientific posters gleaned from reliable online sources and conference proceedings. Additionally, a survey of members of the American Society of Addiction Medicine (ASAM) was administered to assess the practice patterns of experts who treat patients with KUD in isolation of a comorbid opioid use disorder (OUD).

Results: Based on a literature review, 14 reports exist of long-term management of KUD, half of which do not involve a comorbid OUD. Pharmacological modalities utilized include mostly buprenorphine but also a few cases of naltrexone and methadone, all with favorable outcomes. This is supported by the results of the expert survey, which demonstrated that those who have managed KUD in isolation of a comorbid OUD reported having utilized buprenorphine (89.5%), as well as the other medications for opioid use disorder (MOUD).

Conclusions: This is the first comprehensive review to examine the existing literature referring to management of KUD in combination with a survey of current experts’ clinical consensus regarding pharmacological management. Based on this information, it seems reasonable that the indication for MOUD should be extended to cases of moderate to severe KUD.

INTRODUCTION

The increasing consumption of kratom (Mitragyna speciosa) is emerging as a public health concern among Americans, and forecasting models indicate its use will continue to rise.1 Aside from the Food and Drug Administration (FDA) reports of concern2 and adverse effects exhibited through increased calls to poison control centers3 and overdose deaths,4 the notion of addiction is rapidly emerging. In Southeast Asia where this botanical is indigenous, 55% of regular users develop dependence and tolerance. Withdrawal and cravings also have been reported.5-8 There is now substantial evidence showing it is possible for individual kratom users to meet all Diagnostic and Statistical Manual, Fifth Edition (DSM-5) criteria associated with a substance use disorder diagnosis.9 A category for “kratom use disorder” (KUD)—as we coin in this paper—does not formally exist in the DSM-5, which was last revised in 2013. In the United States, a survey of 8,000 users conducted through American Kratom Association (AKA)10 revealed that although some disclosed use with an underlying intent to self-manage opioid misuse including withdrawal, 68% reported using to self-manage chronic pain and 65% for anxiety or mood states, where opioids are not involved at all.

The effects of kratom to date are attributed primarily to the 2 active alkaloids—mitragynine (MG) and 7-hydroxymitragynine (7-HMG)—although more than 25 other alkaloids have been identified in the plant.11 Both exert their primary action through agonism at the μ opiate receptor and weak antagonism at δ and κ receptors.12,13 There is also evidence that MG is involved in sero-
tonergic (antagonist at serotonin 5-HT2A receptors), dopaminergic (agonist at dopamine D1 receptors), and noradrenergic (agonist at postsynaptic alpha-2 receptors) pathways. These translate to users experiencing stimulant-like and opioid-like intoxicating syndromes when either low or high doses are consumed. In traditional medicine, kratom leaves have been used for pain relief; to increase appetite, mood, energy, and sexual desires; to provide wound healing based on anti-inflammatory properties; as a local anesthetic; and to manage coughs, diarrhea, and intestinal infections, among other uses. It is apparent that MG, 7-HMG, and the rest of the plant’s constituents are involved in a multitude of other pathways as well, which have yet to be determined. Although there have been efforts by the FDA to classify MG and 7-HMG as an opioid based on the Public Health Assessment via Structural Evaluation (PHASE) model, this is a very complex botanical with much more unique pharmacodynamic and intracellular signaling actions, hence deserving its own category and classification.

In a previous review of kratom withdrawal, we outlined that symptoms respond akin to that of opioid withdrawal through symptomatic management of a hyperadrenergic state and/or use of opioid receptor agonists (methadone) or partial agonists (buprenorphine). We also alluded to the notion of cravings being present and that there is a high risk of relapse to use on cessation. To date, no guidelines exist regarding the long-term management of KUD. In medical terminology, the “standard of care” is established based on what the average physician in the appropriate specialty community would do when faced with a specific situation. When it comes to KUD management, there is a great need to establish such a standard of care. In this article we report on all the evidence currently available in the literature and combine it with survey information regarding pharmacological management by the addiction medicine specialty community. The aim here is to evaluate potentially beneficial pharmacotherapy only and not specifically any behavioral treatments.

METHODS

Literature Search

We searched PubMed/MEDLINE, PsycINFO, PsycARTICLES, CINAHL, EMBASE, Scopus, Cochrane, and Academic OneFile for English-language medical literature published between January 1, 1970, and January 1, 2020, using the search terms: “kratom,” “mitragyna speciose,” “mitragynine,” and “7-hydroxymitragynine.”

Regarding inclusion and exclusionary criteria, our interest revolved around clinical cases reporting the use of any pharmacotherapy in management of remission from kratom use in both humans and animals. Only English literature was considered.

The original search yielded a total of 2156 returns: PubMed (n = 463), Embase (n = 752), Web of Science (n = 677), CINHAL (n = 182), and PsychINFO (n = 82). After removing duplicates, 671 citations were left. Authors CS and BH examined each by title and abstract. After elimination studies based on exclusionary criteria and applying the inclusion criteria, 14 papers met the original search criteria (Figure 1, Tables 1 and 2). Any disagreements would have been mediated for proper allocation by a third reviewer, but that was not required. Results were supplemented by references gleaned from recent reviews and citations of searched returns, as well as credible reports from academic conferences (Figure 1).

Survey

A survey was designed via Qualtrics (https://www.qualtrics.com) and distributed to the 40 state chapter presidents of the American Society of Addiction Medicine (ASAM), with a request to extend it to their specific membership group. At the time of the survey,
Table 1. Cases Reporting Maintenance Pharmacotherapy of Patients With Kratom Use Disorder and Opioid Use Disorders

<table>
<thead>
<tr>
<th>Ref No.</th>
<th>Clinical Paradigm</th>
<th>Reason for Kratom Use</th>
<th>Extent of Kratom Used</th>
<th>Intervention</th>
<th>Maintenance Regimen</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>16</td>
<td>43-year-old man with history of chronic pain from thoracic outlet syndrome treated with hydromorphone. Started subcutaneously injecting crushed 10 mg tablets of hydromorphone and using kratom to help ameliorate withdrawal when hydromorphone not available. Stopped hydromorphone 3.5 years before presenting and was strictly using kratom. Started taking modafinil 100 mg to help with alertness and presented to ED after experiencing a generalized tonic-clonic seizure. Following discharge, stopped kratom and reported a less intense but more protracted withdrawal compared to opioids persisting for 10 days.</td>
<td>Opioid substitution</td>
<td>Initially used unknown amount of kratom to manage episodic withdrawal from hydromorphone. Ultimately continued using unknown quantity of kratom as a tea 4 x/day; reported spending $15,000/year on kratom.</td>
<td>Started on BUP/NX following withdrawal from kratom to assist with cravings, 16-4 mg.</td>
<td>BUP/NX 16-4 mg/day</td>
<td>Ongoing abstinence confirmed by urine toxicology, maintained on BUP/NX 16-4 mg/day.</td>
</tr>
<tr>
<td>20</td>
<td>52-year-old woman with depression and chronic pain admitted to inpatient psychiatric unit for suicidal ideations. She was experiencing opioid-like withdrawal symptoms. Years prior had developed iatrogenic opioid addiction and switched to kratom 9 months prior to presentation.</td>
<td>Pain management</td>
<td>9 months of use. Gradually increased from 1 tbsp/day powdered plant matter to 1 tbsp 4-6 times/day.</td>
<td>As inpatient, BUP/NX induction occurred, requiring 16/4 mg on day 1 for withdrawal symptoms. Initial plan was for taper but, due to difficulty tapering, was discharged with 2-0.5 mg 4 times/day. BUP/NX increased to 8-2 mg 2x/day to manage cravings as outpatient.</td>
<td>BUP/NX 8-2 mg 2x/day</td>
<td>Ongoing abstinence at 18 months, corroborated via negative urine toxicologies.</td>
</tr>
<tr>
<td>21</td>
<td>32-year-old man with history of PTSD, alcohol use disorder, and OUD in remission from heroin for 2 years. Presented to outpatient clinic for help with kratom dependence.</td>
<td>Energy</td>
<td>8 months of use. Started using 1 capsule kratom product/day; increased to 5-10 capsules/day.</td>
<td>As outpatient, started on BUP/NX 4-1 mg/day; increased to 16-4 mg/day due to withdrawal symptoms.</td>
<td>BUP/NX 16-4 mg/day</td>
<td>No cravings endorsed at follow-up visits; toxicity screens unremarkable.</td>
</tr>
<tr>
<td>22</td>
<td>28-year-old woman at 19 weeks of gestation with history of alcohol use disorder in remission, stimulant (methamphetamine) and OUD (heroin) complicated by a bipolar spectrum disorder; presented to ED for symptoms of withdrawal due to kratom use.</td>
<td>Opioid substitution</td>
<td>4 months of use prior to presentation via smoking; unknown amount, frequency.</td>
<td>Upon admission to inpatient unit, BUP/NX induction occurred. Discharged on 4-1 mg 4 times/day. At 36 weeks gestation, BUP/NX increased to 20-3 mg daily to address withdrawal symptoms.</td>
<td>BUP/NX 4-1 mg 4 x/day; increased to 20-3 mg/day at 36 weeks gestation</td>
<td>Upon induced delivery at 39 weeks, patient continued with BUP/NX 20-3 mg during hospitalization; discharged on it with ongoing abstinence at follow-up.</td>
</tr>
<tr>
<td>23</td>
<td>57-year-old man with chronic back pain, anxiety, depression; originally prescribed oxycodone but developed iatrogenic addiction. After oxycodone was discontinued, transitioned to using kratom 1 year prior to presenting. Noted withdrawal when without kratom and sought help.</td>
<td>Pain management</td>
<td>1 year of use; unknown dose, duration, frequency, route of administration. Purchased from online retailer; spent $2500/month.</td>
<td>Outpatient induction to BUP/NX was performed; patient transitioned to 24-6 mg/day for maintenance.</td>
<td>BUP/NX 24-6 mg daily</td>
<td>Abstinence maintained at 7-month follow-up; confirmed by urine toxicology.</td>
</tr>
<tr>
<td>24</td>
<td>54-year-old man with history of depression, anxiety, and 16-year history of iatrogenic opioid addiction. Used kratom to assist quitting opioids but experienced difficulty when trying to stop. Presented to outpatient addiction treatment clinic for help.</td>
<td>Opioid substitution</td>
<td>Unknown amount, formulation, duration.</td>
<td>Inducted on BUP/NX 8-2 mg on day 1; increased to 16-4 mg on day 2 to target withdrawal symptoms and cravings.</td>
<td>BUP/NX 8-2 mg 2x/day</td>
<td>Maintained abstinence at 2 months while on BUP/NX 8-2 mg 2x/day. Weeks 2-5 post induction, urine mitragynine levels were 52.7, 36.6, 1.2, and &lt;1 ng/mL (negative), respectively.</td>
</tr>
<tr>
<td>25</td>
<td>Report of 9 veterans using kratom in 2013 and 8 more between 2016 and 2017. Two-thirds used kratom daily. One used kratom solely for pain and had an alcohol use disorder. Remainder had history of severe OUD and other substance use disorders. Kratom listed as opioid of choice in 50%; 40% noted tolerance and withdrawal.</td>
<td>Opioid substitution, pain management</td>
<td>Two-thirds had reported daily use of kratom. Formulation included tea/drink, capsules, leaves added to food, or multiple means.</td>
<td>As inpatient, BUP/NX induction occurred. Discharged on 8-2 mg 2x/day. Continued on 24-6 mg. At 18 months, patient was maintained on BUP/NX, referred to a methadone clinic, or treated with naltrexone.</td>
<td>BUP/NX, methadone, naltrexone</td>
<td>All who were opioid dependent were treated with BUP/NX, referred to a methadone clinic, or treated with naltrexone.</td>
</tr>
</tbody>
</table>

Abbreviations: ED, emergency department; BUP/NX, buprenorphine/naloxone; tbsp, tablespoon; PTSD, posttraumatic stress disorder; OUD, opioid use disorder.
ASAM’s membership was 6,365. By using formulas for the maximum error of the estimates, we determined that—for a 95% confidence interval and margin of error of 0.4—a sample size of 564 was required. The survey was distributed initially on January 9, 2020 and was available for 10 days, with 1 brief communication reminder sent during this period to the ASAM chapter presidents. A total of 711 participation invites were sent. Participants were registered electronically through an individualized link, responses were anonymous, and no personal identifiers were collected.

The survey was intended to gauge whether specialists have encountered patients suffering from KUD and how they have managed abstinence in such cases. Our main interest was in pharmacological management of KUD in isolation of past or comorbid OUD histories. Specific questions and flow are detailed in Appendix A.

Eighty-two participants completed the survey, a response rate of 11.5%. Data generated were analyzed via Qualtrics. Some participants who had encountered KUD in isolation of OUD also entered comments regarding management and outcomes (see Appendix B).

RESULTS

Literature Search

The literature review yielded 14 reports involving patients for whom long-term maintenance of KUD was required, including 7 with concomitant OUD diagnoses. Of those 7 patients, all received buprenorphine for maintenance with doses of 16 mg daily; 1 patient required increase from 16 mg to 20 mg due to pregnancy, and another required 24 mg daily. All had switched to kratom use to replace their opioid addiction.

Of the 7 patients without concomitant OUD, 4 were using kratom for pain management, 1 for anxiety/insomnia, 1 for concentration and focus, and 1 patient’s reason for use was unclear. For maintenance, 1 patient was started on naltrexone, and 5 were started on buprenorphine at the following doses: 8 mg eventually tapered to 2 mg prior to pregnancy. 16 mg, 6 mg (2 patients), and 4 mg daily. The other patient was on buprenorphine initially; however, due to chronic pain, he eventually was switched to methadone. See Tables 1 and 2 and Figure 1 for a summary.

Survey

Eighty-two ASAM members completed the survey, and 69 qualified for study inclusion based on their credentials (physicians only). A total of 57 (82.6%) endorsed having encountered patients with KUD, including 19 (27.5%) who had patients with KUD only—no past or comorbid OUD (Figure 2). In managing their abstinence, 17 used buprenorphine (17/19, 89.5%)—including 6 who combined it with talk therapy 1 used methadone, and 3 used naltrexone. Additionally, 1 respondent used buspirone in conjunction with therapy, and another used talk therapy only (Figure 3). (Some of the participant-reported outcomes are included in Appendix B.)

Statistical Analysis

A biostatistician analyzed 2 research questions: (1) Does the proportion of those with kratom addiction in isolation of comorbid OUD from the survey match that found through the literature review? and (2) Among those without comorbid OUD from the survey, does the profile of maintenance modalities match that from the literature review? To address these questions, the survey data was compared with the historical data via a 1-sample proportion test.

Out of the 69 qualifying participants who completed the survey, 57 encountered cases of KUD, including 19 (19/57, 33.3%) cases in isolation of comorbid OUD. This is contrasted to the 14 reports found in the literature, with 7 (7/14, 50%) in isolation of OUD comorbidity. In terms of the profile for maintenance modalities, 17 survey respondents (17/19, 89.5%) endorsed having used buprenorphine maintenance, compared to 6 (6/7, 85.7%) found in the literature. A 1-sample proportion test shows that the proportion in isolation of OUD from the survey is significantly different from the proportion of 0.50 found in the literature (95% CI, 0.22-0.47; P=0.02). Given the small sample size of data and the fact that the upper limit of the confidence interval is close to 0.50, it is reasonable to believe that such a difference is not large. There is no significant difference between the profile of buprenorphine maintenance reported in the survey versus that found in the literatures (95% CI, 0.69-0.97; P=0.64).

DISCUSSION

Kratom is a botanical with a known addiction liability and, in vulnerable individuals, dependence may develop rather quickly with tolerance noted at 3 months and 4- to 10-fold dose escalations required within the first few weeks. Kratom addiction carries a relapse risk as high as 78% to 89% at 3 months post-cessation. Although there are numerous pathways that kratom’s constituents act upon, the opioid pathway has received the most interest with respect to mediation of withdrawal and addiction. This is consistent with the notion that stimulant effects are noted at low doses—5 grams or less daily, while opioid effects at higher doses and the doses used by those addicted to it indeed seem to range from 14 grams to 42 grams daily. Unfortunately, most of the cases included in our review do not reference doses. In the 3 that do (all without comorbid OUD), 1 describes an individual using 7 grams every 4 hours, and 2 involve doses of 30 grams daily. One of the experts surveyed also mentioned having managed patients with histories of 30 grams daily use.

There are 2 main pathways describing how individuals are introduced to kratom—opioid substitution by those with OUD and self-management of various ailments (ie, anxiety and mood states, pain) by those without OUD. The cases included in this review corroborate this notion. For patients with OUD, relapse rates without MOUD are in the 90% range—similar to relapse rates without MOUD.
### Table 2. Cases Reporting Maintenance Pharmacotherapy of Patients With Kratom Use Disorder Without Co-occurring Opioid Use Disorder

<table>
<thead>
<tr>
<th>Ref No.</th>
<th>Clinical Paradigm</th>
<th>Reason for Kratom Use</th>
<th>Extent of Kratom Used</th>
<th>Intervention</th>
<th>Maintenance Regimen</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>22</td>
<td>32-year-old woman at 22 weeks gestation presented to specialty clinic for pregnant women with substance use disorders. Had previously undergone radiation for Hodgkin’s lymphoma, resulting in chronic shoulder pain and anxiety. Managed on oxycodone until previous pregnancy, but had been self-managing with kratom for previous 7 months. Attempted to stop kratom at 16 weeks gestation but resumed due to withdrawal.</td>
<td>Pain management, anxiety</td>
<td>7 months of use; unknown dose, duration, frequency, and route of administration.</td>
<td>After kratom abstinence period, patient started on BUP as outpatient; reported good results with 8 mg/day. Given concern of neonatal abstinence syndrome, tapered off BUP over 2 weeks but experienced severe depression and was restarted and maintained on 2 mg for remainder of pregnancy.</td>
<td>BUP 2 mg during pregnancy</td>
<td>Upon planned C-section at 39 weeks gestation, patient maintained on BUP; abstinence maintained at follow-up visits.</td>
</tr>
<tr>
<td>23</td>
<td>60-year-old woman with chronic pain and history of alcohol dependence in sustained remission presented following unintentional overdose on illicit methadone. No history of OUD; endorsed kratom use and was on a long-term opioid regimen with tramadol and oxycodone with no evidence of misuse. Discharged following admission and stabilization, but presented several months later because of difficulty stopping kratom due to rebound pain and withdrawal symptoms.</td>
<td>Pain management</td>
<td>At time of evaluation, 0.25 ounces every 4 hours; purchased via online retailer.</td>
<td>Outpatient induction to BUP/NX performed; patient then transitioned to 4-1 mg 4 x/day maintenance.</td>
<td>BUP/NX 4-1 mg 4x/day</td>
<td>Abstinence maintained at 9-month follow-up; confirmed by urine toxicology.</td>
</tr>
<tr>
<td>26</td>
<td>37-year-old woman with history of postpartum depression and 2-year history of kratom use to self-manage pain stemming from fibromyalgia and after surgery for carpal tunnel syndrome. Experienced withdrawal symptoms when trying to cut back; attempted outpatient detox with low-dose clonidine without success. Contacted mental health and addiction service for inpatient kratom detox; ultimately admitted for inpatient detox.</td>
<td>Pain management</td>
<td>Started using unknown amount of kratom capsules; transitioned to using kratom extract purchased from online retailer over 2 years.</td>
<td>As inpatient, treated with symptom-triggered clonidine protocol and supportive medications for 3 days prior to discharge.</td>
<td>Naltrexone 50 mg/day</td>
<td>Patient discharged to partial hospitalization program and instructed to start oral naltrexone on day 7 post-discharge.</td>
</tr>
<tr>
<td>27</td>
<td>20-year-old man with history of ADHD (treated with stimulant) presented to office-based addiction treatment clinic for KUD management. Had used kratom past 2 years to manage anxiety and insomnia but developed tolerance. Cessation attempts led to opioid-like withdrawal.</td>
<td>Anxiety, insomnia</td>
<td>2 years of use; increased gradually to every 2 hours for 30 g total daily dose. Obtained from local gas station and mixed with water into tea.</td>
<td>Outpatient induction to BUP/NX performed, starting with 4-1 mg 12 hours after last kratom use and with moderate withdrawal. Attempt to taper to 2-0.5 mg over 4 days resulted in withdrawal symptoms and dose was brought back up.</td>
<td>BUP/NX 4-1 mg daily</td>
<td>Noted difficulty tapering off BUP/NX with supervision. After 3 months treatment, had 1 setback on kratom when out of BUP/NX. Has maintained sobriety after several months, working to taper off BUP/NX.</td>
</tr>
<tr>
<td>28</td>
<td>35-year-old male veteran presented to addiction treatment clinic reporting escalating kratom use over past 3 years. Started using kratom for concentration but use gradually increased and became singular focus over work, school, and personal activity. Was able to reduce from 30g daily to 5g/day following motivational interviewing, but experienced withdrawal.</td>
<td>Focus, concentration</td>
<td>Daily use increased from 10 g/day initially to 30 g/day. First obtained from gas station; consumed in smoothie or shake form.</td>
<td>Outpatient induction to BUP/NX performed, 4-1 mg 2x/day.</td>
<td>BUP/NX 8-2 mg/day for 16 months, then decreased to 6-1.5 mg/day</td>
<td>BUP/NX increased to 12-3 mg to target evening cravings; decreased back to 8-2 mg/day due to sedation. Maintained abstinence at 16 months, corroborated by urine toxicology screens for mitragynine. After 16 months, BUP/NX dose decreased to 6-1.5 mg/day, with goal of tapering off over 1 year.</td>
</tr>
<tr>
<td>29</td>
<td>24-year-old man with history of alcohol use disorder, Asperger’s, and kratom use presented to ED after being found down, minimally responsive, hypothermic, and having a witnessed seizure by emergency medical personnel. Upon stabilization in ICU, was transferred to inpatient psychiatric unit.</td>
<td>Unclear duration, but was using 600 mg/day prior to presentation.</td>
<td>BUP 2 mg started on hospital day 13 on psychiatric ward to target kratom cravings. On day 25, BUP increased to 4 mg 2x/day due to persistent signs/symptoms of withdrawal. Discharged to a rehab center on day 28. BUP discontinued initially but restarted at 2-0.5 mg 3x/day due to withdrawal symptoms.</td>
<td>BUP/NX 2-0.5 mg 3x/day.</td>
<td>Tapered off BUP/NX after 45 days at rehab center and discharged home.</td>
<td></td>
</tr>
</tbody>
</table>
rates for KUD—versus less than 50% when MOUD are implemented.\textsuperscript{7,8,32} Hence, for those with both OUD and KUD, it is logical to utilize MOUD. In all such cases reported above, buprenorphine was used with good results in terms of opioid and kratom abstinence.

There is a clear need to establish a consensus on how to manage KUD independent of an OUD. As demonstrated in this review, there has been success with treating KUD using the same pharmacological agents as those approved for OUD. In the cases included here that did not involve a comorbid OUD diagnosis, clinicians have utilized naltrexone (n=1 case) and buprenorphine for maintenance. The use of MOUD to treat KUD has been hindered historically by the medicolegal aspects governing these agents, yet reports of treatment do exist and are corroborated by results of the survey conducted as part of this review.

There is pharmacodynamic evidence to suggest for those with OUD, ~70% mu receptor occupancy is required to achieve suppression of psychological aspects of opioid addiction.\textsuperscript{40} Depending on the severity of one’s OUD, for example high dose and intravenous use, upwards of 90% occupancy may be required.\textsuperscript{41} Although the first may be achieved with 2-3 ng/mL plasma concentration of buprenorphine (corresponding with 8-16 mg oral dose), the latter would require 5-6 ng/mL (corresponding to 20-32 mg oral dose).\textsuperscript{41} It is still uncertain what the opioid receptor dynamic with MG and 7-HMG is, however, it is believed that—at least for MG—it is very similar to buprenorphine.\textsuperscript{12,13} From the cases included here, it appears that lower buprenorphine doses tend to be required for KUD in absence of OUD. Antagonist treatment has even been used in 1 case.

**Limitations**

The cases resulting from the literature search and included in the analysis/comparison have a significant amount of heterogeneity in the descriptions, information provided (ie, kratom dose, route, etc), toxicology screens used for abstinence monitoring, reporting of maintenance follow-up duration, etc. Nonetheless, they all used buprenorphine or naltrexone for management of long-term abstinence as a general consensus.

**Table 2 continued.** Cases Reporting Maintenance Pharmacotherapy of Patients With Kratom Use Disorder Without Co-occurring Opioid Use Disorder

<table>
<thead>
<tr>
<th>Ref No.</th>
<th>Clinical Paradigm</th>
<th>Reason for Kratom Use</th>
<th>Extent of Kratom Used</th>
<th>Intervention</th>
<th>Maintenance Regimen</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>30</td>
<td>44-year-old man with history of alcohol use disorder presented to detox unit for help stopping kratom. Began use after brief use of nonprescription oxycodone for chronic abdominal pain. Noted difficulty stopping after 1 year due to withdrawal.</td>
<td>Pain management</td>
<td>1 year of use. Initially used a “tincture” dosed by “dropper squeeze;” gradually increased to “6 drop per squeezes” every 4-6 hours.</td>
<td>Inpatient induction to BUP to help with withdrawal.</td>
<td>At 15 months post-discharge revealed use of oral opiates, including methadone and oxycodone, for chronic pain syndrome.</td>
<td></td>
</tr>
</tbody>
</table>

Abbreviations: BUP/NX, buprenorphine/naloxone; OUD, opioid use disorder; detox, detoxification; ADHD, attention deficit hyperactivity disorder; ED, emergency department.

**CONCLUSION**

Through our survey, we assessed clinical practice patterns for management of KUD without the confounding OUD diagnosis, which would be a clear indication MOUD—the standard of care. A substantial number of respondents (82.6%) have encountered cases of KUD, of which the majority involved a comorbid OUD diagnosis. Those who endorsed treating cases of kratom addiction that did not involve a comorbid OUD reported having used primarily buprenorphine (89.5%) to manage abstinence, with the
rest using naltrexone and methadone. Based on some of the comments in Appendix B, the outcomes have been good and, like with OUD, counseling alone is not sufficient.

Together, the literature review and survey data suggest that a standard of care for maintenance of abstinence from kratom use in those with KUD hints towards the use of MOUD. This is especially true for individuals with histories of using in excess of 24 grams of kratom daily. The maintenance buprenorphine doses seem to be lower than those needed for OUD.

In light of the detrimental risks associated with growing reports of kratom use disorder and lack of any randomized controlled trials to explore treatment, this review provides sufficient evidence that the indication of MOUD should be extended to KUD as well. This is especially true if one’s use of kratom involves high doses and meets DSM-5 diagnostic criteria for a moderate or severe substance use disorder.

Acknowledgements: The authors would like to acknowledge the contribution made by Karen Goodman, MS, LIS, MA; Medical Librarian Dorothy M. Breene Memorial Library at New Hampshire Hospital, as well as Elizabeth Jenkins, MS(LIS), Education and Information Services Librarian at Boston University Alumni Medical Library for their assistance with the literature search and procurement of articles needed for this review.

Funding/Support: None declared.

Financial Disclosures: None declared.

Appendices: Available at www.wmjonline.org.

REFERENCES

7. SinghD, MüllerCP, VicknasingamBK. Kratom (Mitragyna speciosa) dependence, withdrawal symptoms and craving in regular users. Drug Alcohol Depend. 2014;139:122-137. doi:10.1016/j.drugalcdep.2014.03.017